FBI "Scientific Research Institute of Oncology n. a. N. N. Petrov"

Saint Petersburg 197758

0 studies enrolling now · 9 studies all time

What they study most

Advanced BRAFV600 Wild-type Melanoma, Carcinoma, Non-Small-Cell Lung, First Line Non-Small Cell Lung Cancer, Gastric Adenocarcinoma, Invasive Fungal Infections, Locally Advanced or Metastatic and Unresectable HCC, Metastatic Breast Cancer, Metastatic Melanoma, Non-small Cell Lung Cancer

Studies at this site

• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) — Running, not enrolling
• Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed
• A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma — Completed
• Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options — Completed
• Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma — Stopped early
• A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC — Completed
• A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma — Stopped early
• Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) — Completed
• Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer — Completed